Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Despite previous challenges, CSL offers potential growth and stability with improving plasma collections and strong demand for its healthcare products.
  • Known for its notable dividend yield of approximately 11%, Accent presents an attractive option for income-focused investors keen on retail sector resilience.
  • Both CSL and Accent are compelling options for those seeking either long-term growth or immediate income as the year draws to a close.

As Christmas approaches, plenty of investors start thinking about where to put fresh money to work before the new year. I am no different. With markets still a bit choppy and sentiment mixed across sectors, I have been focusing on quality businesses where the risk-reward balance looks attractive heading into 2026.

Two ASX shares are standing out to me right now, despite sitting at opposite ends of the market. For different reasons, both are worth a closer look.

ecommerce asx shares represented by santa doing online shopping on laptop

Image source: Getty Images

CSL Ltd (ASX: CSL)

The CSL share price has had a tough run over the past year and is trading around $175, well below the levels investors had become used to. Softer profit guidance, higher costs, and a slower-than-expected recovery in plasma collections weighed on sentiment, and the market did not take kindly to that.

That being said, the long-term story has not broken. Plasma collections have been improving, Seqirus continues to perform solidly, and CSL Vifor is starting to settle after a challenging integration period. Cost discipline is also coming into focus, which is usually the first step toward margin recovery.

Several brokers continue to describe CSL as oversold, with price targets well above current levels. For a global healthcare leader with a long track record of growth, a strong balance sheet, and solid demand for immunoglobulin and vaccines, the current share price is starting to look far more appealing than it did a year ago.

If CSL can show steadier execution across FY26, the share price could start to find support.

Accent Group Ltd (ASX: AX1)

At the other end of the spectrum sits Accent, with its share price trading around 90 cents. The footwear retailer owns well-known brands such as Platypus, Hype DC and The Athlete's Foot, and it has built a strong omnichannel business across Australia and New Zealand.

What really stands out here is income. Accent paid 10 cents per share in fully franked dividends over the past year, which puts the trailing yield at roughly 11% at current prices. That is a big number for an ASX 200 stock.

While retail always carries some risk, Accent has performed better than many of its peers, with resilient margins and solid digital sales. Management continues to invest in store rollouts and owned brands, which support earnings over time.

For income-focused investors who are comfortable with some volatility, Accent offers a level of yield that is hard to ignore.

Foolish Takeaway

CSL and Accent Group are very different businesses, but both stand out to me as we head into Christmas. CSL offers quality and long-term growth at a much lower price than usual, while Accent provides immediate income at an attractive yield.

For investors looking to add ideas before the year ends, these two ASX shares are well worth having on the watchlist.

Motley Fool contributor Aaron Teboneras has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Accent Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

CSL shares rebound 79% from multi-year low: Here's what brokers tip next

The ASX biotech company announced its FY26 results yesterday.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months

Find out what brokers tip for this ASX healthcare stock next.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Earnings Results

Healius posts FY26 revenue growth, narrows underlying loss

Its underlying loss narrowed, but its reported loss after tax widened to $415.6 million.

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

CSL shares just had their best day in 20 years. What did I just miss?

A US$2.6 billion loss sent CSL shares soaring. Here is why.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

EBOS FY26 earnings: profit edges higher, dividend steady

EBOS Group posts a rise in FY26 profit and revenue as it maintains its final dividend for shareholders.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Bell Potter tips more than 140% upside for this out of favour ASX biotech

This company has made good progress over the past quarter.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »